Elizabeth Garrett-Mayer to Prostate-Specific Antigen
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Prostate-Specific Antigen.
Connection Strength
0.307
-
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 01; 25(25):3965-70.
Score: 0.066
-
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar 07; 99(5):376-85.
Score: 0.064
-
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003 Jul 02; 95(13):990-1000.
Score: 0.049
-
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
Score: 0.022
-
Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology. 2010 Nov; 76(5):1162-7.
Score: 0.021
-
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010 Jan 01; 16(1):203-11.
Score: 0.019
-
Effect of DNA methylation on identification of aggressive prostate cancer. Urology. 2008 Dec; 72(6):1234-9.
Score: 0.017
-
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007 Nov 01; 13(21):6396-403.
Score: 0.017
-
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
Score: 0.016
-
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar; 69(3):526-31.
Score: 0.016